M&A Deal Summary

Assertio Acquires Zyla Life Sciences

On March 16, 2020, Assertio acquired life science company Zyla Life Sciences

Acquisition Highlights
  • This is Assertio’s 1st transaction in the Life Science sector.
  • This is Assertio’s 2nd transaction in the United States.
  • This is Assertio’s 1st transaction in Pennsylvania.

M&A Deal Summary
Date 2020-03-16
Target Zyla Life Sciences
Sector Life Science
Buyer(s) Assertio
Deal Type Merger
Advisor(s) MTS Health Partners LP (Financial)
Dechert (Legal)

Target

Zyla Life Sciences

Wayne, Pennsylvania, United States
Zyla Life Sciences is a business committed to bringing important products to patients and healthcare providers. Zyla is focused on marketing its portfolio of medicines for pain and inflammation. Zyla Life Sciences portfolio includes six products: SPRIX® (ketorolac tromethamine) Nasal Spray, ZORVOLEX® (diclofenac), VIVLODEX® (meloxicam), INDOCIN® (indomethacin) suppositories, INDOCIN® oral suspension and OXAYDO® (oxycodone HCI, USP) tablets for oral use only - CII. Zyla Life Sciences was founded in 2010 and is based in Wayne, Pennsylvania.

Search 201,771 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Assertio

Lake Forest, Illinois, United States
Category Company
Founded 1995
Sector Life Science
Employees53
Revenue 152M USD (2023)
DESCRIPTION

Assertio is a pharmaceutical company focused on products to treat pain and other central nervous system (CNS) conditions. Assertio was founded in 1995 and is based in Lake Forest, Illinois.

DEAL STATS #
Overall 2 of 4
Sector (Life Science) 1 of 3
Type (Merger) 1 of 1
State (Pennsylvania) 1 of 1
Country (United States) 2 of 4
Year (2020) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-02-06 Assertio Therapeutics - NUCYNTA

California, United States

Assertio Therapeutics, Inc. - NUCYNTA is a strong prescription pain medicine that contains an opioid (narcotic) that is used to manage short-term (acute) pain in adults when other pain treatments, such as non-opioid pain medicines, do not treat your pain well enough or you cannot tolerate them.

Sell $375M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-12-15 Otrexup

New Jersey, United States

Otrexup is a drug-device combination single dose once weekly auto-injector containing a prescription medicine, methotrexate, which is indicated for certain adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis (pJIA), after treatment with other medicines including non-steroidal anti-inflammatory drugs (NSAIDS) have been used and did not work well. It is also used to control the symptoms of severe, resistant, disabling psoriasis in adults when other types of treatment have been used and did not work well.

Buy $44M
Mergr

Product

Company

Legal